Table 2.
Medications of patients with type 2 diabetes
| VFA<100 cm2 |
VFA≥100 cm2 |
p Value* | |||
|---|---|---|---|---|---|
| BMI<25 kg/m2 OB(−)VA(−) (N=157) |
BMI≥25 kg/m2 OB(+)VA(−) (N=49) |
BMI<25 kg/m2 OB(−)VA(+) (N=30) |
BMI≥25 kg/m2 OB(+)VA(+) (N=178) |
||
| OHA (%) | 43 | 47 | 43 | 58 | 0.036 |
| Sulfonylureas (%) | 15 | 6 | 7 | 10 | 0.229 |
| Biguanides (%) | 13 | 20 | 17 | 33 | <0.001 |
| α-GIs (%) | 11 | 6 | 3 | 5 | 0.169 |
| TZDs (%) | 2 | 2 | 7 | 6 | 0.180 |
| DPP4 inhibitors (%) | 31 | 16 | 17 | 23 | 0.082 |
| Glinides (%) | 4 | 6 | 10 | 3 | 0.267 |
| SGLT2 inhibitors (%) | 0 | 0 | 0 | 2 | 0.261 |
| GLP-1 agonists (%) | 1 | 4 | 7 | 12 | <0.001 |
| Insulin (%) | 76 | 69 | 60 | 68 | 0.015 |
| ACEIs (%) | 6 | 4 | 3 | 3 | 0.602 |
| ARBs (%) | 30 | 53 | 53 | 53 | <0.001 |
| MRBs (%) | 3 | 0 | 0 | 4 | 0.350 |
| CCBs (%) | 25 | 41 | 40 | 39 | 0.022 |
| β-Blockers (%) | 10 | 10 | 0 | 10 | 0.339 |
| α-Blockers (%) | 2 | 2 | 0 | 2 | 0.876 |
| Diuretics (%) | 8 | 8 | 7 | 13 | 0.277 |
| Statins (%) | 42 | 43 | 47 | 53 | 0.231 |
| Fibrates (%) | 0 | 2 | 10 | 4 | 0.008 |
| Ezetimib (%) | 4 | 0 | 0 | 3 | 0.322 |
| UA lowering agents (%) | 1 | 6 | 7 | 7 | 0.069 |
| Antiplatelets (%) | 20 | 10 | 13 | 23 | 0.184 |
Data are expressed as percentage.
*χ2 test.
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; CCB, calcium channel blocker; DPP4, dipeptidyl peptidase-4; GI, glycosidase inhibitor; GLP-1, glucagon-like peptide-1; MRB, mineral corticoid receptor blocker; OHA, oral hypoglycemic agent; SGLT2, sodium-glucose co-transporter 2; TZD, thiazolidinedione; UA, uric acid; VFA, visceral fat area.